AmacaThera
AmacaThera is a clinical-stage biotechnology company focused on transforming therapeutics to improve patient health. Utilizing a unique injectable hydrogel platform, the company aims to provide localized, sustained drug delivery across various therapeutic areas, including post-surgical pain management and cancer treatment.
AmacaThera
MaRS Centre, West Tower, 661 University Ave Suite 1300, Toronto, ON M5G 0B7
What We Do
An opioid-free formulation for sustained release of an anesthetic using the AmacaGel platform, designed to provide post-operative pain control without the need for opioids.
FDA Regulated Medical Devices
Drugs
Application Area
Show More (5)Key People
News & Updates
Media coverage highlighting AmacaThera’s drug development platform and start-up journey.
Press release announcing the first human subject dosed with AMT-143, aimed at non-opioid acute pain management.
Press release regarding the closing of a CAD$4.0 million financing round to advance clinical development.